Login to Your Account



Financings Roundup

Achillion to Raise $50M in Stock Offering for HCV Studies

By Catherine Hollingsworth


Friday, August 20, 2010
Achillion Pharmaceuticals Inc. plans to raise about $50 million through the sale of stock and warrants to a select group of investors, money that would be used to advance the company's early stage pipeline of drug candidates for hepatitis C virus (HCV). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription